News Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Delayed Australian S.E. Other stock markets 01:00:06 15/05/2024 BST			5-day change	1st Jan Change
0.029 ^AUD	0.00%		-9.38%	+31.82%

05-07	Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer	MT
05-03	Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer	05-07	MT
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	05-03	MT
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	04-22	CI
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	04-22	MT
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	04-15	CI
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	04-15	MT
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	03-25	MT
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	03-07	MT
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-25	CI
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	02-15	MT
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer’s Disease Trial	12-20	MT
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	11-28	CI
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone	11-28	MT
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	11-28	MT
Actinogen Medical Names CFO	11-08	MT
Actinogen Medical Limited Announces CFO Changes	11-07	CI
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	13/10/23	CI
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug	27/09/23	MT
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	26/09/23	CI
Actinogen Medical Completes AU$10 Rights Issue	07/09/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Summary

Filters